Royalty Report: Drugs, Cancer, Biotechnology – Collection: 178353

License Grant

Licensor hereby grants to Licensee a non-transferable, exclusive license, with the right to sublicense, under the Licensed Property and Licensed Patent Rights and Licensed Know-How, solely to the extent necessary to research, discover, develop, make, have made, use, sell, offer to sell, export and import Licensed compounds and/or licensed products in the field in the territory.

License Property

The licensed property is United States Patent 9091696B2 Modulation of NR2F6 and methods and uses thereof;  United States Provisional Patent Application # i62/363588 Small Molecule Modulators of NR2F6 Activity and additional patent applications and provisional patents relating to the above and Silenced Autologous Immunotherapeutics; Methods of screening compounds that can modulate NR2F6 by displacement of a reference Ligand and Method of cancer treatment using Sirna Silencing.

United States Patent # 9091696B2
“MODULATION OF NR2F6 AND METHODS
AND USES THEREOF”
United States Provisional Patent Application # i62/363588 “Small Molecule Modulators of NR2F6 Activity”
2223-224 Regen BioPharma Modulation of NR2F6 and methods of use…
13/652,395 Utility 10/15/2012 11/16/2009
Regen-ImmnoThrptcsNP1 Regen BioPharma NR2F6 SILENCED AUTOLOGOUS
IMMUNOTHERAPEUTICS 15299400 Utility 10/20/2016 10/20/2015
Regen-ImmnoThrptcsPR1 Regen BioPharma NR2F6 Silenced Autologous
Immunotherapeutics 62243792 Utility (Provisional) 10/20/2015 10/20/2015
Regen-NR2F6ChimericNP1 Regen BioPharma NR2F6 Inhibited Chimeric Antigen
Receptor Cells 15351414 Utility 11/14/2016 11/12/2015
Regen-NR2F6ChimericPR1 Regen BioPharma NR2F6 Inhibited Chimeric Antigen
Receptor Cells 62254330 Utility (Provisional) 11/12/2015 11/12/2015
Regen-Personalized-PR1 Regen BioPharma Personalized T Cell Immunotherapy
Utilizing NR2F6 Gene Silencing 62276619 Utility (Provisional) 01/08/2016
> 01/08/2016
Regen-SmallMoleculeNP1 Regen BioPharma SMALL MOLECULE MODULATORS OF NR2F6
ACTIVITY 15364111 11/29/2016 11/29/2015
Regen-SmallMoleculePR1 Regen BioPharma Small Molecule Modulators of NR2F6
Activity 62260617 Utility (Provisional) 11/29/2015 11/29/2015
Regen-UDCI-PR1 Regen BioPharma Universal Donor Checkpoint Inhibitor
Silenced/Gene Edited Cord Blood Killer Cells 62327245 Utility (Provisional)
04/25/2016 04/25/2016
RegenBioPharma-CIP2 Regen BioPharma Methods and Compositions for treatment
of cancer by inhibition of NR2F6 14/571,262 Utility 12/15/2014 11/14/2008
RegenBioPharma-CIP3 Regen BioPharma Treatment of Myelodysplastic Syndrome
by Inhibition of NR2F6 14/572,574 Utility 12/16/2014 11/14/2008
RegenBioPharma-CIP4 Regen BioPharma Treatment of Myelodysplastic Syndrome
by Inhibition of NR2F2 14/588,374 Utility 12/31/2014 11/14/2008
RegenBioPharma-CIP5 Regen BioPharma Methods and Compositions for treatment
of cancer by inhibition of NR2F2 14/588,373 Utility 12/31/2014 11/14/2008
RegenBioPharma-CIP6 Regen BioPharma Modulation of Hematopoietic Stem Cell
Differentiation 14/595,078 Utility 01/12/2015 11/14/2008
RegenBioPharma-CIP7 Regen BioPharma METHODS OF SCREENING COMPOUNDS THAT CAN
MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND 14852623 Utility
> 09/13/2015 11/14/2008
RegenIL-17-PR1 Regen BioPharma Methods and Means of Generating IL-17
Associated Antitumor Effector Cells by Inhibition of NR2F6 Inhibition
62294007 Utility (Provisional) 02/11/2016 02/11/2016
RegenIL-18-PR1 Regen BioPharma Modulation of IL-18 Production through
Modification of NR2F6 Activity 62293828 Utility (Provisional) 02/11/2016
> 02/11/2016
RN11917593 Regen BioPharma METHOD OF CANCER TREATMENT USING SIRNA SILENCING
11/917,593 Utility 06/15/2006 06/15/2005

Field of Use

The license field of use means all therapeutic uses related to treatment of diseases in humans only.

License Grant

Licensor hereby grants to Licensee an exclusive, royalty-bearing right and license, in the Field in the Territory, including the right to grant sublicenses, to make, have made, use, develop, commercialize, offer for sale, have sold, and import Licensed Products.

License Property

Patent Rights shall mean
9,091,696 – Modulation of NR2F6 and methods and uses thereof
10,088,485 – Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand

Field of Use

Field shall mean therapeutic uses related to treatment in humans of colon cancer.

License Grant

Licensor grants to Licensee an exclusive, royalty-bearing right and license, in the Field in the Territory, including the right to grant sublicenses, under the Licensed Technology, to Develop, make, have made, use, Commercialize, offer for sale, have sold, and import Licensed Products. Field shall mean the use of Licensed Technology in the veterinary Non Human Field for therapeutic purposes.

License Property

The Licensor is a biotechnology company, focused on the development of regenerative medical applications in the United States, including provisional Patent Antigen Specific mRNA Cellular Cancer Vaccines, United States, 62165116, Provisional, 05/21/2015.

Field of Use

Licensee desires to obtain from Licensor an exclusive right and License for the development and commercialization of the License IP for non-human veterinary therapeutic use.  Licensee is developing products treating blood disorders using small molecules based on nuclear receptor NR2F6.

License Grant

The Licensor hereby grants to the Licensee an exclusive license under the Licensed Rights to under the Licensed Property.  The Licensee has a unique opportunity to accelerate our development by utilizing intellectual property, drug leads, new research technologies, technical know-how and original scientific concepts derived from 25 years of research achievements relevant to cancer by licensed patent applications and patents.

License Property

CCF Technology shall mean all CCF’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (I) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Provisional Patent Application 60/526,538 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,666 – Methods of Identifying of Modulators of Apoptosis From Parasites and Uses Thereof U.S. Provisional Patent Application 60/526,496 – Methods of Inhibiting Apoptosis Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,667 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,460 – Methods of Protecting Against Radiation Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,461 – Methods of Protecting Against Radiation Using Flagellin U.S. Provisional Patent Application 60/571,149 – Small Molecules Inhibitors of MRP1 and Other Multi drug Transporters U.S. Provisional Patent Application 60/589,637 – Activation of p53 and Inhibition of NF-kB for cancer treatment.

Field of Use

Licensed Field shall mean shall mean the practice, production, manufacture, sale and use of the Licensed Rights for the discovery, development and commercialization of methods, techniques, devices, systems, animals and therapeutics in the field of regulating cell death

CBLC100 series small molecules that restore the activity of p53 tumor suppressor in cancers, including renal cell carcinomas, sarcomas, prostate cancers and other types of malignancies; curaxines and derivatives thereof are representative examples of this category;
CBLB101 series substances of biological nature (i.e., cytokine, chemokines and other secreted molecules) and their bioactive derivatives produced by tumor cells and capable of modulating cell survival; TGFß2 and derivatives thereof and derivatives thereof are representative examples of this category;
CBLB501 series natural factors produced by extracellular parasites and symbiont of humans and other mammalian species and their bioactive derivatives capable of modulating cell survival mechanisms of host cells; flagellin of Salmonella typhimurium and derivatives thereof are representative examples of this category;
CBLC500 series small molecules modulating tumor and normal cell sensitivity to cytotoxic chemicals by altering activity and substrate specificity of multi drug transporters; inhibitors of MRP1 and derivatives thereof are representative examples of this category.

License Grant

The Canadian Licensor, a non-profit academic health research institute, grants to the Canadian Licensee the exclusive, world-wide, right and license, with the right to sublieense, to use Licensors rights in and to the Licensed Technology and the Licensed Patents in the Field of Use to develop Licensed Products and to make, have made, import, use, offer for sale and sell Licensed Products.

License Property

License relates to certain patents relating to the use of Wnt7a proteins.

Licensor owns technologies relating to protein and small molecule therapies for the treatment of diseases.

1. A Pax-Encoding Vector And Use Thereof US (CIP) 7,384,784

2. Methods And Compositions For Modulating Stem Cell Growth And Differentiation US 7,541,183

3. Novel Stem Cells, Nucleotide Sequences And Proteins Therefrom US 12/094,585

4. Use Of Cardiotropbln To Modulate Stem Cell Proliferation US 11/318,413

5. Pancreatic Regeneration PCT/CA2009/001220

6. Treatment of Muscle Disease Characterized by Insulin Resistance US Provisional 61/179,040

7. Composition and Methods for Modulating Stem Cells US Provisional 61/172,832

8. Cardiac Stem Cell Proliferation Proteins, Fragments Thereof And Methods Of Modulating Stem Cell Proliferation And Differentiation US 12/156,953

9. Prodrugs of Biguanlde Derlvatlves For The Treatment of Muscular Disorders US Provisional 61/244,669

Field of Use

Licensee has identified Wnt7a as a natural promoter of SSCs to drive muscle regeneration and are initially focused on developing Wnt7a protein analogs for the treatment of muscular dystrophies. Licensee believes that our regenerative approach for treating muscular dystrophies holds significant therapeutic promise and is distinct from other approaches, which focus on preventing muscle degeneration.

Field of Use means all fields.